Evidence map›Paper›PMID 38177531›Full record

ArticleEMBO molecular medicine2024

Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression.

Oscar Molina, Carmen Ortega-Sabater, Namitha Thampi, Narcís Fernández-Fuentes, Mercedes Guerrero-Murillo, Alba Martínez-Moreno, Meritxell Vinyoles, Talía Velasco-Hernández, Clara Bueno, Juan L Trincado and 16 more

Open access · goldAbstract read
In one paragraph

Article in EMBO molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Chromosomal Instability Drives Glioblastoma Heterogeneity and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 13 institutions in 5 countries.

Oscar MolinaJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. omolina@carrerasresearch.org.ORCID http://orcid.org/0000-0001-7585-4519
Carmen Ortega-Sabater *Mathematical Oncology Laboratory, Department of Mathematics & Institute of Applied Mathematics in Science and Engineering, Universidad de Castilla-La Mancha, Ciudad Real, Spain.
Namitha Thampi *Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6166-583X
Narcís Fernández-FuentesJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6421-1080
Mercedes Guerrero-MurilloJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5556-2460
Alba Martínez-MorenoJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7514-260X
Meritxell VinyolesJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1906-4701
Talía Velasco-HernándezJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2183-7443
Clara BuenoJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
Juan L TrincadoJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-5363-3774
Isabel GranadaHematology Service, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Badalona, Spain.
Diana CamposDiNA Science, S.A, Barcelona, Spain.
Carles GiménezDiNA Science, S.A, Barcelona, Spain.
Judith M BoerPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-4848-7789
Monique L den BoerPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Gabriel F CalvoMathematical Oncology Laboratory, Department of Mathematics & Institute of Applied Mathematics in Science and Engineering, Universidad de Castilla-La Mancha, Ciudad Real, Spain.ORCID http://orcid.org/0000-0002-3623-236X
Mireia CamósHematology Laboratory, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Jose-Luis FusterPediatric Hematology and Oncology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.ORCID http://orcid.org/0000-0002-4881-9440
Pablo VelascoPediatric Oncology and Hematology Department, Hospital Vall d'Hebrón, Barcelona, Spain.
Paola BalleriniAP-HP, Service of Pediatric Hematology, Hopital Armand Trousseau, Paris, France.ORCID http://orcid.org/0009-0005-4844-7762
Franco LocatelliBambino Gesù Children's Hospital, Catholic University of Sacred Heart, Rome, Italy.ORCID http://orcid.org/0000-0002-7976-3654
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-1871-1850
Diana C J SpieringsEuropean Research Institute for the Biology of Aging (ERIBA), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-8403-474X
Floris FoijerEuropean Research Institute for the Biology of Aging (ERIBA), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-0989-3127
Víctor M Pérez-GarcíaMathematical Oncology Laboratory, Department of Mathematics & Institute of Applied Mathematics in Science and Engineering, Universidad de Castilla-La Mancha, Ciudad Real, Spain.ORCID http://orcid.org/0000-0002-6575-495X
Pablo MenéndezJosep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. pmenendez@carrerasresearch.org.ORCID http://orcid.org/0000-0001-9372-1007
Instituto de Salud Carlos III · ESUniversity of Castilla-La Mancha · ESBarcelona School of Economics · ESPrincess Máxima Center · NLUniversity Medical Center Groningen · NLBambino Gesù Children's Hospital · ITHospital Sant Joan de Déu Barcelona · ESInstitució Catalana de Recerca i Estudis Avançats · ESInstituto Murciano de Investigación Biosanitaria · ESJosep Carreras Leukaemia Research Institute · ESSorbonne Université · FRSt. Jude Children's Research Hospital · USVall d'Hebron Hospital Universitari · ES

Funding

Fundación Científica Asociación Española Contra el Cáncer (AECC) INVES211226MOLIFundación Josep Carreras Contra la Leucemia (Josep Carreras Leukaemia Foundation) DJCLS 15 R/2023Government of Catalonia | Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) 2022/SGR-003MEC | Instituto de Salud Carlos III (ISCIII) PI17/01028MEC | Instituto de Salud Carlos III (ISCIII) PI20/00822MEC | Instituto de Salud Carlos III (ISCIII) RD21/0017/0029Ministerio de Ciencia e Innovación (MCIN) PDC2022-133520-I00Ministerio de Ciencia e Innovación (MCIN) PID2019-110895RB-I00Ministerio de Ciencia e Innovación (MCIN) PID2022-142341OB-I00Ministerio de Ciencia e Innovación (MCIN) TED2021-132296B-C55Ministerio de Economía y Competitividad (MEC) PID2022-142966OB-I00
6 · The paper itself

Abstract

Chromosomal instability (CIN) lies at the core of cancer development leading to aneuploidy, chromosomal copy-number heterogeneity (chr-CNH) and ultimately, unfavorable clinical outcomes. Despite its ubiquity in cancer, the presence of CIN in childhood B-cell acute lymphoblastic leukemia (cB-ALL), the most frequent pediatric cancer showing high frequencies of aneuploidy, remains unknown. Here, we elucidate the presence of CIN in aneuploid cB-ALL subtypes using single-cell whole-genome sequencing of primary cB-ALL samples and by generating and functionally characterizing patient-derived xenograft models (cB-ALL-PDX). We report higher rates of CIN across aneuploid than in euploid cB-ALL that strongly correlate with intraclonal chr-CNH and overall survival in mice. This association was further supported by in silico mathematical modeling. Moreover, mass-spectrometry analyses of cB-ALL-PDX revealed a "CIN signature" enriched in mitotic-spindle regulatory pathways, which was confirmed by RNA-sequencing of a large cohort of cB-ALL samples. The link between the presence of CIN in aneuploid cB-ALL and disease progression opens new possibilities for patient stratification and offers a promising new avenue as a therapeutic target in cB-ALL treatment.

Indexed as

AneuploidyPrecursor Cell Lymphoblastic Leukemia-LymphomaAnimalsChildChromosomal InstabilityDisease ProgressionHumansMiceChromosomal Instability; Aneuploidy; Childhood B-cell Acute Lymphoblastic Leukemia; Disease Models

Identifiers

PMID38177531
PMCPMC10897411
OpenAlexW4389941059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.